Reuters exclusively reported that U.S. drugmaker AbbVie Inc is in discussions to sell a roughly $5 billion portfolio of women’s drugs acquired last year through its $63 billion purchase of Botox maker Allergan Plc. The move revives a process to sell the business, which makes the Lo Loestrin Fe birth control pill, that Allergan started in 2018 only to ditch five months before being acquired by AbbVie in 2019.
The post Reuters exclusively reports AbbVie in talks to sell $5 billion women’s drugs portfolio appeared first on Reuters News Agency.
